Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
Nasdaq15d
Axsome Therapeutics Receives FDA Approval for SYMBRAVO, a Novel Acute Treatment for Migraine Pain Relief
The novel multi-mechanistic design of SYMBRAVO is a promising advancement, targeting multiple pathways involved in migraine attacks, indicating ... last 6 months: MARK L. JACOBSON (Chief Operating ...